HOUSTON--(BUSINESS WIRE)--Stem Cell Innovations, Inc., or “SCI” (OTCBB: SCLL) announced today that James H. Kelly, Ph.D, Chief Executive Officer of Stem Cell Innovations (SCI), Inc. will present data at the Stem Cells World Congress in San Diego describing further characterization and extension of SCI’s PluriCell™ stem cell system. The Congress draws together experts from academia and industry to discuss progress in the stem cell arena. In particular, Dr. Kelly will describe the ability of PluriCells™ to become endothelial cells, the cells that line the arteries and which are central players in cardiovascular disease. Normal adults have few circulating endothelial precursors in their blood but increased levels have been shown in conditions associated with myocardial infarction and stroke. PluriCells™ can provide both a drug discovery platform and also a potential cell therapy for use in these conditions.
